Clinical Trial Update: Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy

View source ↗

Summary

A clinical trial evaluating whether Veristrat, a biomarker test, can predict which patients with non-small cell lung cancer will benefit from first-line standar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Conditions: Non Small Cell Lung Cancer | Status: UNKNOWN